Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 13/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446197 | 0.86 | TNK2 (0.58) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL16445963 | 0.86 | TNK2 (0.58) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL16445965 | 0.86 | TNK2 (0.58) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL21460565 | 0.85 | HPGD (0.50) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL21478068 | 0.85 | HPGD (0.50) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL7262019 | 0.85 | HPGD (0.50) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL16446172 | 0.84 | KMT2A (0.53) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL18488972 | 0.83 | TNK2 (0.54) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL23620371 | 0.80 | HCAR3 (0.53) | TNK2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL4071077 | 0.79 | KMT2A (0.42) | TNK2IGF1RMEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| WO-2015021149-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885IGF1R 810/4885ALDH1A1 3704/4885 |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | TNK2 3/4885IGF1R 810/4885ALDH1A1 3704/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885IGF1R 810/4885ALDH1A1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.